Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy

Seminars in Nuclear Medicine

Volumn 40, Issue 3, 2010, Pages 209-218

  Pool, Stefan E ^a   Krenning, Eric P ^a   Koning, Gerben A ^a   van Eijck, Casper H J ^a   Teunissen, Jaap J M ^a   Kam, Boen ^a   Valkema, Roelf ^a   Kwekkeboom, Dik J ^a   de Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID EXENDIN 4 IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE[3 TYROSINE]; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE[3 TYROSINE] LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE[3 TYROSINE] Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE]; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] Y 90; BOMBESIN DERIVATIVE; BOMBESIN[13 LEUCINE] TC 99M; CAPECITABINE; CISPLATIN; DEMOBESIN1 TC 99M; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EXENDIN 4; FLUOROURACIL; INDIUM 111; LUTETIUM 177; OCTREOTIDE[3 TYROSINE]; ONALTA; PENTETIC ACID; PENTETIC ACID PENTETREOTIDE IN 111; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOISOTOPE; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; CHILL; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC IMAGING; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; ELECTRON; FEVER; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HYPOTENSION; INSULINOMA; ISOTOPE LABELING; LIVER METASTASIS; MONOTHERAPY; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PARAGANGLIOMA; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIATION DOSE; RADIOISOTOPE THERAPY; RENAL PROTECTION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA; VOMITING;

ALPHA PARTICLES; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; ISOTOPE LABELING; NEOPLASMS; PEPTIDES; RADIOISOTOPES; RECEPTORS, PEPTIDE;

EID: 77949895194     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.12.001     Document Type: Review

References (117)

1. Schottelius M., and Wester H.J. Molecular imaging targeting peptide receptors. Methods 48 (2009) 161-177
2. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24 (2003) 389-427
3. Krenning E.P., Kwekkeboom D.J., Bakker W.H., et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20 (1993) 716-731
4. Reubi J.C., Schar J.C., Waser B., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 (2000) 273-282
5. Valkema R., De Jong M., Bakker W.H., et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Semin Nucl Med 32 (2002) 110-122
6. Otte A., Mueller-Brand J., Dellas S., et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351 (1998) 417-418
7. Teunissen J.J., Kwekkeboom D.J., de Jong M., et al. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (2005) 595-616
8. Waldherr C., Pless M., Maecke H.R., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43 (2002) 610-616
9. van Essen M., Krenning E.P., Kam B.L., et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 5 (2009) 382-393
10. Anthony L.B., Woltering E.A., Espenan G.D., et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32 (2002) 123-132
11. Baum R.P. Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors. Eur J Nucl Med 31 (2004) S238
12. Baum R.P. Peptidreceptorvermittelte Radiotherapie (PRRT) neuroendocriner tumoren klinischen Indikationen und erfahrung mit 90Yttrium-markierten Somatostatinanaloga der. Onkologe 10 (2004) 1098-1110
13. Bodei L., Cremonesi M., Zoboli S., et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 30 (2003) 207-216
14. Buscombe J.R., Caplin M.E., and Hilson A.J. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 44 (2003) 1-6
15. Delpassand E.S., Sims-Mourtada J., Saso H., et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm 23 (2008) 292-300
16. Frilling A., Weber F., Saner F., et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 140 (2006) 968-976 discussion 976-977
17. Kwekkeboom D.J., de Herder W.W., Kam B.L., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26 (2008) 2124-2130
18. Limouris G.S., Chatziioannou A., Kontogeorgakos D., et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 35 (2008) 1827-1837
19. Valkema R., Pauwels S., Kvols L.K., et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36 (2006) 147-156
20. Virgolini I., Britton K., Buscombe J., et al. In- and Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial. Semin Nucl Med 32 (2002) 148-155
21. Waldherr C., Schumacher T., Maecke H.R., et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90yttrium-DOTATOC in neuroendocrine tumors?. Eur J Nucl Med 29 (2002) S100
22. Waldherr C., Pless M., Maecke H.R., et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12 (2001) 941-945
23. Duncan J.R., Stephenson M.T., Wu H.P., et al. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 57 (1997) 659-671
24. Capello A., Krenning E.P., Breeman W.A., et al. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. J Nucl Med 44 (2003) 98-104
25. Capello A., Krenning E., Bernard B., et al. 111In-labelled somatostatin analogues in a rat tumour model: Somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 32 (2005) 1288-1295
26. Khan S., Teunissen J.J.M., van Essen M., et al. Quality of life in 265 patients with gastroenteropancreatic tumours or bronchial carcinoids treated with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging 36 (2009) S219
27. Teunissen J.J., Kwekkeboom D.J., and Krenning E.P. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol 22 (2004) 2724-2729
28. Capello A., Krenning E.P., Breeman W.A., et al. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: Peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm 18 (2003) 761-768
29. de Jong M., Breeman W.A., Bakker W.H., et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58 (1998) 437-441
30. de Jong M., Breeman W.A., Bernard B.F., et al. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 42 (2001) 1841-1846
31. Lewis J.S., Lewis M.R., Srinivasan A., et al. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 42 (1999) 1341-1347
32. Forrer F., Uusijarvi H., Waldherr C., et al. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: Biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31 (2004) 1257-1262
33. Esser J.P., Krenning E.P., Teunissen J.J., et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: Which peptide is preferable for PRRT?. Eur J Nucl Med Mol Imaging 33 (2006) 1346-1351
34. van Essen M., Krenning E.P., Bakker W.H., et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 34 (2007) 1219-1227
35. van Essen M., Krenning E.P., Kooij P.P., et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 47 (2006) 1599-1606
36. Forrer F., Riedweg I., Maecke H.R., et al. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 52 (2008) 334-340
37. Wild D., Schmitt J.S., Ginj M., et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30 (2003) 1338-1347
38. Ginj M., Schmitt J.S., Chen J., et al. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol 13 (2006) 1081-1090
39. 68Ga-DOTATATE PET/CT in the detection of GEP NETs. Eur J Nucl Med Mol Imaging 36 (2009) S201
40. Ginj M., Zhang H., Eisenwiener K.P., et al. New pansomatostatin ligands and their chelated versions: Affinity profile, agonist activity, internalization, and tumor targeting. Clin Cancer Res 14 (2008) 2019-2027
41. Liu Q., Cescato R., Dewi D.A., et al. Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol Pharmacol 68 (2005) 90-101
42. Wynn P.C., Suarez-Quian C.A., Childs G.V., et al. Pituitary binding and internalization of radioiodinated gonadotropin-releasing hormone agonist and antagonist ligands in vitro and in vivo. Endocrinology 119 (1986) 1852-1863
43. Ginj M., Zhang H., Waser B., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 103 (2006) 16436-16441
44. Nock B., Nikolopoulou A., Chiotellis E., et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 30 (2003) 247-258
45. Korner M., Stockli M., Waser B., et al. GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J Nucl Med 48 (2007) 736-743
46. Gotthardt M., Fischer M., Naeher I., et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: Initial experimental results. Eur J Nucl Med Mol Imaging 29 (2002) 597-606
47. Gotthardt M., Lalyko G., van Eerd-Vismale J., et al. A new technique for in vivo imaging of specific GLP-1 binding sites: First results in small rodents. Regul Pept 137 (2006) 162-167
48. Wild D., Behe M., Wicki A., et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 47 (2006) 2025-2033
49. Wicki A., Wild D., Storch D., et al. [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 13 (2007) 3696-3705
50. Rolleman EJ, Melis M, Valkema R, et al: Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging (in press)
51. Wild D., Wicki A., Christofori G., et al. Combination therapy with [(Lys40(Ahx-[111In-DTPA])]-exendin-4 and VEGF-receptor tyrosine kinase inhibitor PTK in a glucagon-like-peptide-1 receptor-positive transgenic mouse tumor model. J Nucl Med 48 (2007) 83p
52. Christ E., Wild D., Forrer F., et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 94 (2009) 4398-4405
53. Reubi J.C., Wenger S., Schmuckli-Maurer J., et al. Bombesin receptor subtypes in human cancers: Detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 8 (2002) 1139-1146
54. Nock B.A., Nikolopoulou A., Galanis A., et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: A preclinical study. J Med Chem 48 (2005) 100-110
55. Van de Wiele C., Dumont F., Vanden Broecke R., et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: A feasibility study. Eur J Nucl Med 27 (2000) 1694-1699
56. Hoffman T.J., Gali H., Smith C.J., et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 44 (2003) 823-831
57. Breeman W.A., de Jong M., Erion J.L., et al. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 43 (2002) 1650-1656
58. Ferro-Flores G., Arteaga de Murphy C., Rodriguez-Cortes J., et al. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun 27 (2006) 371-376
59. Garcia Garayoa E., Ruegg D., Blauenstein P., et al. Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. Nucl Med Biol 34 (2007) 17-28
60. Schroeder R, Muller C, Reneman S, et al: Selection of the best bombesin analogue for use in phase I trial imaging prostate cancer with SPECT. (in press)
61. Schroeder R.P., van Weerden W.M., Bangma C., et al. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 48 (2009) 200-204
62. Bodei L., Ferrari M., Nunn A., et al. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: A phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging 34 (2007) 463
63. Varvarigou A.D., Scopinaro F., Leondiadis L., et al. Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide. Cancer Biother Radiopharm 17 (2002) 317-326
64. De Vincentis G., Scopinaro F., Varvarigou A., et al. Phase I trial of technetium [Leu13] bombesin as cancer seeking agent: Possible scintigraphic guide for surgery?. Tumori 88 (2002) S28-S30
65. De Vincentis G., Remediani S., Varvarigou A.D., et al. Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother Radiopharm 19 (2004) 81-84
66. Scopinaro F., De Vincentis G., Varvarigou A.D., et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 30 (2003) 1378-1382
67. Hofmann M., Machtens S., Stief C., et al. Feasibility of Ga-68-DOTABOM PET in prostate carcinoma patients. Eur J Nucl Med Mol Imaging 31 (2004) S253
68. Froberg A.C., Visser M., Maina T., et al. Are GRP-receptors present in the human pancreas?. J Nucl Med 47 (2006) 429P
69. Reubi J.C., Chayvialle J.A., Franc B., et al. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 64 (1991) 567-573
70. Kwekkeboom D.J., Reubi J.C., Lamberts S.W., et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76 (1993) 1413-1417
71. Reubi J.C., Schaer J.C., and Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57 (1997) 1377-1386
72. Kwekkeboom D.J., Bakker W.H., Kooij P.P., et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 27 (2000) 1312-1317
73. Laverman P., Roosenburg S., Gotthardt M., et al. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. Eur J Nucl Med Mol Imaging 35 (2008) 386-392
74. Behr T.M., Jenner N., Radetzky S., et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 25 (1998) 424-430
75. von Guggenberg E., Sallegger W., Helbok A., et al. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: Preclinical evaluation. J Med Chem 52 (2009) 4786-4793
76. Behr T.M., Jenner N., Behe M., et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 40 (1999) 1029-1044
77. Nock B.A., Maina T., Behe M., et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 46 (2005) 1727-1736
78. Froberg A.C., de Jong M., Nock B.A., et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 36 (2009) 1265-1272
79. Gotthardt M., Behe M.P., Beuter D., et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 33 (2006) 1273-1279
80. Plow E.F., Haas T.A., Zhang L., et al. Ligand binding to integrins. J Biol Chem 275 (2000) 21785-21788
81. van Hagen P.M., Breeman W.A., Bernard H.F., et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 90 (2000) 186-198
82. Chen X., Liu S., Hou Y., et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6 (2004) 350-359
83. Chen X., Tohme M., Park R., et al. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 3 (2004) 96-104
84. Cai W., Zhang X., Wu Y., et al. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med 47 (2006) 1172-1180
85. Haubner R., Kuhnast B., Mang C., et al. [18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15 (2004) 61-69
86. Beer A.J., Haubner R., Sarbia M., et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 12 (2006) 3942-3949
87. Beer A.J., Haubner R., Goebel M., et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 46 (2005) 1333-1341
88. Dijkgraaf I., Kruijtzer J.A., Liu S., et al. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging 34 (2007) 267-273
89. Dijkgraaf I., Rijnders A.Y., Soede A., et al. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: Implications for tumor targeting and tumor imaging purposes. Org Biomol Chem 5 (2007) 935-944
90. Dijkgraaf I., Kruijtzer J.A., Frielink C., et al. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 120 (2007) 605-610
91. Klijn J.G., Berns P.M., Schmitz P.I., et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 13 (1992) 3-17
92. Chen P., Cameron R., Wang J., et al. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 44 (2003) 1469-1478
93. Cuartero-Plaza A., Martinez-Miralles E., Rosell R., et al. Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res 2 (1996) 13-20
94. Tolmachev V, Rosik D, Wallberg H, et al: Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR (111)In-DOTA-Z (EGFR:2377) Affibody molecule: Aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging (in press)
95. Kwekkeboom D.J., Teunissen J.J., Bakker W.H., et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23 (2005) 2754-2762
96. O'Donoghue J.A., Bardies M., and Wheldon T.E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36 (1995) 1902-1909
97. de Jong M., Breeman W.A., Valkema R., et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46 suppl 1 (2005) 13S-17S
98. de Jong M., Breeman W.A., Bernard B.F., et al. [177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 92 (2001) 628-633
99. De Jong M., Valkema R., Jamar F., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140
100. Kunikowska J., Krolicki L., Hubalewska-Dydejczk A., et al. Comparison between clinical results of PRRT with 90Y-DOTATATE and 90Y/177Lu-DOTATATE. Eur J Nucl Med Mol Imaging 36 (2009) S219
101. McStay M.K., Maudgil D., Williams M., et al. Large-volume liver metastases from neuroendocrine tumors: Hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 237 (2005) 718-726
102. Brogsitter C., Pinkert J., Bredow J., et al. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG. J Nucl Med 46 (2005) 2112-2116
103. Pool S.E., Kam B., Breeman W.A.P., et al. Increasing intrahepatic tumour uptake of 111In-DTPA-octreotide by loco regional administration. Eur J Nucl Med Mol Imaging 36 (2009) S427
104. Dieleman S., Verwijnen S., Berndsen S.C., et al. Increased tumour versus background ratio of radiolabelled octreotide: Intratumoural versus intravenous injection. Eur J Nucl Med Mol Imaging 36 (2009) S404
105. Beauregard J.M., Eu P., Neels O.C., et al. Enhanced uptake in neuroendocrine tumours after intraarterial infusion of [68Ga/177Lu]-octreotate. Eur J Nucl Med Mol Imaging 36 (2009) S278
106. Gotthardt M., Librizzi D., Wolf D., et al. Increased therapeutic efficacy through combination of Lu-177-DOTATOC and chemotherapy in neuroendocrine tumors in vivo. Eur J Nucl Med Mol Imaging 33 (2006) S115
107. Kong G., Lau E., Ramdave S., et al. High-dose 111In-octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumors. J Nucl Med 46 (2005) 151P
108. van Essen M., Krenning E.P., Kam B.L., et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 35 (2008) 743-748
109. Lambert B., Cybulla M., Weiner S.M., et al. Renal toxicity after radionuclide therapy. Radiat Res 161 (2004) 607-611
110. Kwekkeboom D.J., Mueller-Brand J., Paganelli G., et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46 suppl 1 (2005) 62S-66S
111. Valkema R., Pauwels S.A., Kvols L.K., et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 46 suppl 1 (2005) 83S-91S
112. Melis M., Krenning E.P., Bernard B.F., et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 32 (2005) 1136-1143
113. De Jong M., Valkema R., Van Gameren A., et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J Nucl Med 45 (2004) 1168-1171
114. de Jong M., Barone R., Krenning E., et al. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. J Nucl Med 46 (2005) 1696-1700
115. Rolleman E.J., Kooij P.P., de Herder W.W., et al. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging 34 (2007) 1854-1860
116. Verwijnen S.M., Krenning E.P., Valkema R., et al. Oral versus intravenous administration of lysine: Equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotide. J Nucl Med 46 (2005) 2057-2060
117. Rolleman E.J., Forrer F., Bernard B., et al. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 34 (2007) 763-771